New psychosis treatment targets genetic mutation instead of symptoms

A novel treatment that targets the biological effects of a specific genetic mutation could help alleviate the symptoms of psychosis, a new study finds.

Deborah L. Levy, Ph.D. — from the McLean Hospital in Belmont, MA — led the new study, the findings of which now appear in the journal Biological Psychiatry.

It revealed that people who had additional copies of a certain gene, instead of the regular two, benefited from the treatment.

The mutation, called a copy number variant (CNV), affects the glycine decarboxylase gene.

Full story at Medical News Today